Cargando…
Developmental Pharmacogenetics in Pediatric Rheumatology: Utilizing a New Paradigm to Effectively Treat Patients with Juvenile Idiopathic Arthritis with Methotrexate
Although methotrexate is widely used in clinical practice there remains significant lack of understanding of its mechanisms of action and the factors that contribute to the variability in toxicity and response seen clinically. In addition to differences in drug administration, factors that affect ph...
Autores principales: | Becker, Mara L., Leeder, J. Steven |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958653/ https://www.ncbi.nlm.nih.gov/pubmed/20981233 http://dx.doi.org/10.4061/2010/257120 |
Ejemplares similares
-
PReS-FINAL-2165: Pharmacogenetic determinants of response to methotrexate in juvenile idiopathic arthritis
por: Pastore, S, et al.
Publicado: (2013) -
Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro
por: Funk, RS, et al.
Publicado: (2016) -
3019 Metabolomic Markers of Methotrexate Response in Juvenile Idiopathic Arthritis
por: Funk, Ryan Sol, et al.
Publicado: (2019) -
Predictors of response to methotrexate in juvenile idiopathic arthritis
por: Albarouni, Mohamed, et al.
Publicado: (2014) -
Access to pediatric rheumatology care for Juvenile Idiopathic Arthritis in the United Arab Emirates
por: Khawaja, Khulood, et al.
Publicado: (2017)